AZN vs JNJ vs VRTX Stock Comparison

Astrazeneca, Johnson & Johnson and Vertex Pharmaceuticals Prices as of Nov 13, 2026 Peers: Industry group
AZN Astrazeneca Plc
$184.49 +13.8% 1M +4.1% 1Y
Market cap
$285.34B
P/E
25.9x
Revenue (TTM)
$59.37B
Div. yield
–
Pharmaceuticals Healthcare
5 wins
JNJ Johnson & Johnson
$286.11 +12.7% 1M +46.5% 1Y
Market cap
$682.35B
P/E
42.4x
Revenue (TTM)
$99.34B
Div. yield
0.02%
Pharmaceuticals Healthcare
3 wins

Head to Head

11 decided of 12

Astrazeneca leads on 5 of the 12 questions below (Astrazeneca 5, Johnson & Johnson 3, Vertex Pharmaceuticals 3). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAZNJNJVRTXLeader
Larger companyMarket capitalisation $285.34B $682.35B $136.07B JNJ
Cheaper on earningsLower P/E, profitable companies only 25.9x 42.4x 34.2x AZN
Cheaper on forward earningsLower price / next fiscal year consensus EPS 18.4x 26.7x 30.4x AZN
Faster revenue growthRevenue growth, trailing twelve months +7.8% +7.8% +10.5% VRTX
More profitableNet margin, trailing twelve months 18.6% 16.2% 30.7% VRTX
Better return on capitalReturn on invested capital 23.1% 17.6% — AZN
Less leveragedLower net debt / EBITDA -0.7x 0.8x -0.4x AZN
Higher dividend yieldTrailing dividend yield 0.00% 0.02% 0.00% –
Better 1-year returnPrice return, last 12 months +4.1% +46.5% +24.0% JNJ
Better 5-year returnAnnualised price return, 5 years +9.4%/yr +11.6%/yr +23.5%/yr VRTX
Less volatileAnnualised volatility, 1 year 28.1% 21.2% 29.5% JNJ
Higher overall scoreMean of the five percentile scores vs peers 74/100 65/100 73/100 AZN

Percentile Scorecard

AZNJNJVRTX

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAZNJNJVRTX
Valuation 85 #102 of 660 84 #104 of 660 77 #152 of 660
Growth 57 #268 of 619 34 #410 of 619 46 #333 of 619
Profitability 94 #36 of 595 94 #39 of 595 93 #40 of 595
Financial Health 65 #237 of 683 39 #416 of 683 55 #311 of 683
Shareholder Returns 67 #151 of 459 73 #123 of 459 92 #37 of 459
Overall 74 65 73
  • AZN ranked among 695 companies in Pharmaceuticals and Biotechnology
  • JNJ ranked among 695 companies in Pharmaceuticals and Biotechnology
  • VRTX ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAZNJNJVRTXSPY
1 month +13.8%+12.7%+8.0% -2.0%
3 months +17.9%+9.9%+6.5% -2.8%
6 months +1.6%+26.2%+23.3% +2.0%
Year to date +0.3%+38.3%+18.8% +10.6%
1 year +4.1%+46.5%+24.0% +12.2%
3 years +43.6%+93.8%+45.6% +68.1%
3 years, per year +12.8%+24.7%+13.3% +18.9%
5 years +56.9%+73.4%+187.6% +61.4%
5 years, per year +9.4%+11.6%+23.5% +10.1%
10 years +229.7%+141.5%+485.4% +248.5%
10 years, per year +12.7%+9.2%+19.3% +13.3%

Risk

MeasureAZNJNJVRTXSPY
Volatility, 1Y 28.1%21.2%29.5% 13.6%
Downside volatility, 1Y 26.9%20.1%26.1% 13.9%
Beta vs S&P 500, 1Y 0.19-0.090.43 1.00
Return / volatility, 1Y 0.152.190.81 0.90
Max drawdown, 5Y -27.9%-23.6%-29.1% -25.4%
From 52-week high -11.9%0.0%-3.6% -3.2%
52-week high $209.48$286.11$558.71 $779.14
52-week low $155.60$195.25$421.03 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAZNJNJVRTX
P/E now vs peer median 25.9xmedian 17.0x 42.8xmedian 17.0x 34.3xmedian 17.0x
P/S now vs peer median 4.8xmedian 8.4x 6.9xmedian 8.4x 10.5xmedian 8.4x
EV/EBITDA now vs peer median 12.8xmedian 14.6x 21.5xmedian 14.6x 29.7xmedian 14.6x
P/FCF now vs peer median 26.9xmedian 19.0x 33.5xmedian 19.0x 42.6xmedian 19.0x
P/B now vs peer median 5.5xmedian 2.0x 8.4xmedian 2.0x 6.5xmedian 2.0x
PEG now vs peer median 1.12median 0.43 -1.42median 0.43 6.39median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAZNJNJVRTX
Revenue $59.37B $99.34B $12.95B
Gross profit $51.12B $67.11B $11.08B
Operating income $14.78B $25.19B $4.30B
Net income $11.03B $16.10B $3.98B
Free cash flow $10.63B $20.59B $3.20B
R&D $15.30B $16.08B $4.25B
EPS (diluted) $7.06 $6.57 $15.58
Cash & equivalents $7.94B $16.91B $4.98B
Total debt -$5.53B $44.65B $4.50B
Shares (diluted) 1.56B 2.45B 255.20M
Enterprise value $258.99B $602.21B $103.81B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAZNJNJVRTX
P/E 25.9x 42.8x 34.3x
P/FCF 26.9x 33.5x 42.6x
P/Operating cash flow 21.6x 26.3x 37.0x
P/S 4.8x 6.9x 10.5x
P/B 5.5x 8.4x 6.5x
P/Tangible book 20.9x 19.7x 11.0x
EV/EBITDA 12.8x 21.5x 29.7x
EV/EBIT 18.3x 28.4x 31.3x
EV/Revenue 4.6x 7.2x 10.4x
EV/FCF 25.5x 34.8x 42.1x
EV/Operating cash flow 20.5x 27.4x 36.5x
PEG (3Y EPS CAGR) 1.12 -1.42 6.39

Growth

14 metrics
MetricAZNJNJVRTX
Revenue growth (1Y) 7.8% 7.8% 10.5%
Revenue CAGR (3Y) 10.3% -14.5% 10.3%
Gross profit growth (1Y) 6.7% 7.0% 9.5%
Gross profit CAGR (3Y) 12.3% -12.3% 9.3%
Operating income growth (1Y) 15.4% 7.4% 7.8%
Operating income CAGR (3Y) 22.6% -12.8% 3.5%
Net income growth (1Y) 17.3% -35.9% 8.2%
Net income CAGR (3Y) 23.2% -31.0% 4.6%
EPS growth (1Y) 17.5% -36.4% 9.2%
EPS CAGR (3Y) 23.2% -30.1% 5.4%
Operating cash flow growth (1Y) -12.6% 8.1% -0.6%
Operating cash flow CAGR (3Y) – 11.4% -5.5%
Free cash flow growth (1Y) -22.8% 5.1% -4.0%
Free cash flow CAGR (3Y) – 8.8% -8.7%

Profitability

14 metrics
MetricAZNJNJVRTX
Gross margin 86.1% 67.6% 85.5%
EBITDA margin 35.7% 33.5% 35.1%
Operating margin 24.9% 25.4% 33.2%
Pretax margin 22.4% 17.9% 36.7%
Net margin 18.6% 16.2% 30.7%
FCF margin 17.9% 20.7% 24.7%
Operating cash flow margin 22.3% 26.3% 28.5%
Return on equity 21.6% 19.3% 19.3%
Return on assets 9.4% 8.1% 13.2%
Return on invested capital 23.1% 17.6% –
Return on capital employed 9.9% 17.5% 17.2%
Asset turnover 0.5x 0.5x 0.4x
Cash conversion (OCF / net income) 1.2x 1.6x 0.9x
Stock comp / revenue – 1.4% 5.2%

Financial Health

11 metrics
MetricAZNJNJVRTX
Debt / assets -5.6% 22.6% 13.7%
Debt / equity -0.1x 0.5x 0.2x
Net debt / EBITDA -0.7x 0.8x -0.4x
Debt / FCF -0.6x 2.2x 1.4x
Liabilities / assets 56.8% 58.7% 36.1%
Equity / assets 43.2% 41.3% 63.9%
Interest coverage 16.1x 25.6x 93.0x
Current ratio -1.0x 1.0x 2.3x
Quick ratio -0.8x 0.7x 1.7x
Cash ratio -0.3x 0.3x 1.3x
Altman Z-score 4.21 5.69 8.70

Shareholder Returns

7 metrics
MetricAZNJNJVRTX
Dividend yield 1.3% 1.8% –
Net buyback yield 0.0% 0.6% 0.7%
Shareholder yield 1.3% 2.4% 0.7%
Payout ratio (earnings) – 79.0% –
Payout ratio (FCF) – 61.8% –
Dividend growth (1Y) – 3.9% –
Dividend CAGR (3Y) – 2.8% –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAZNJNJVRTX
Forward P/E 18.4xFY2026 26.7xFY2026 30.4xFY2026
EPS, next fiscal year $10.00FY2026 $10.72FY2026 $17.71FY2026
EPS growth, next FY +9.2%FY2026 -0.6%FY2026 -3.7%FY2026
EPS growth, the year after +5.7% +5.8% +20.2%
Revenue, next fiscal year $58.85BFY2026 $106.55BFY2026 $12.68BFY2026
Revenue growth, next FY +0.2%FY2026 +13.1%FY2026 +5.9%FY2026
Revenue growth, the year after +7.8% +6.8% +19.2%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAZNJNJVRTX
Held by institutions 52.1% 74.7% 95.1%
Institutions holding 1,498 4,699 1,747
Change in shares held, QoQ +7.8% +1.8% +3.9%
Institutions buying 809 2,297 904
Institutions selling 469 1,899 605
Buyers to sellers 1.72 1.21 1.49

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AZNJNJVRTX
AZN 1.00 0.47 0.47
JNJ 0.47 1.00 0.41
VRTX 0.47 0.41 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AZN, JNJ and VRTX?

Johnson & Johnson (JNJ) is the largest by market capitalisation: Astrazeneca (AZN) $285.34B, Johnson & Johnson (JNJ) $682.35B, Vertex Pharmaceuticals (VRTX) $136.07B.

Which stock is cheaper, AZN, JNJ and VRTX?

Astrazeneca (AZN) trades on the lowest price-to-earnings ratio (Astrazeneca (AZN) 25.9x, Johnson & Johnson (JNJ) 42.4x, Vertex Pharmaceuticals (VRTX) 34.2x). On next year's consensus earnings, Astrazeneca (AZN) is cheapest (Astrazeneca (AZN) 18.4x, Johnson & Johnson (JNJ) 26.7x, Vertex Pharmaceuticals (VRTX) 30.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Vertex Pharmaceuticals (VRTX) grew revenue fastest over the trailing twelve months: Astrazeneca (AZN) +7.8%, Johnson & Johnson (JNJ) +7.8%, Vertex Pharmaceuticals (VRTX) +10.5%.

Which company is more profitable?

Vertex Pharmaceuticals (VRTX) has the highest net margin (Astrazeneca (AZN) 18.6%, Johnson & Johnson (JNJ) 16.2%, Vertex Pharmaceuticals (VRTX) 30.7%). On return on invested capital, Astrazeneca (AZN) leads (Astrazeneca (AZN) 23.1%, Johnson & Johnson (JNJ) 17.6%).

Which stock has performed better?

Over the past year Johnson & Johnson (JNJ) returned the most: Astrazeneca (AZN) +4.1%, Johnson & Johnson (JNJ) +46.5%, Vertex Pharmaceuticals (VRTX) +24.0%. Over five years, Vertex Pharmaceuticals (VRTX) compounded fastest (Astrazeneca (AZN) +9.4%/yr, Johnson & Johnson (JNJ) +11.6%/yr, Vertex Pharmaceuticals (VRTX) +23.5%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Astrazeneca (AZN) 0.00%, Johnson & Johnson (JNJ) 0.02%, Vertex Pharmaceuticals (VRTX) 0.00%. Astrazeneca (AZN) and Vertex Pharmaceuticals (VRTX) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Johnson & Johnson (JNJ) has been the steadiest (Astrazeneca (AZN) 28.1%, Johnson & Johnson (JNJ) 21.2%, Vertex Pharmaceuticals (VRTX) 29.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, AZN, JNJ and VRTX?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Astrazeneca (AZN) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.